Advertisement
Advertisement
KALV
KalVista Pharmaceuticals, Inc. Common Stock
26.73
USDSponsored
+0.01
+0.04%
May 08, 16:00 UTC -4
Closed
Pre-Market
26.73
0.00
0.00%
KALV Earnings Reports
Positive Surprise Ratio
KALV beat 25 of 36 last estimates.
69%
Next Report
Date of Next Report
--
Estimate for Q-- -- (Revenue/ EPS)
--
/--
Implied change from Q4 25 (Revenue/ EPS)
--
/--
Implied change from Q-- -- (Revenue/ EPS)
--
/--
KalVista Pharmaceuticals, Inc. Common Stock earnings per share and revenue
On Mar 25, 2026, KALV reported earnings of 0.91 USD per share (EPS) for Q4 25, beating the estimate of -0.47 USD, resulting in a 291.25% surprise. Revenue reached --, compared to an expected --, with a --% difference. The market reacted with a +4.13% price change (close before vs. close after earnings).
Looking ahead to -- --, -- analysts forecast an EPS of -- USD, with revenue projected to reach -- USD, implying an -- of --% EPS, and -- of --% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Amylyx Pharmaceuticals, Inc. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.33
Actual
-$0.37
Surprise
-9.82%
Collegium Pharmaceutical, Inc. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
$1.62
Actual
$1.76
Surprise
+8.43%
4D Molecular Therapeutics, Inc. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
-$1.01
Actual
-$1.01
Surprise
+0.21%
Akebia Therapeutics, Inc.
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.02
Actual
-$0.03
Surprise
-4.90%
Organogenesis Holdings Inc. Class A Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.31
Actual
-$0.37
Surprise
-17.01%
OmniAb, Inc. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.10
Actual
-$0.06
Surprise
+41.18%
Stevanato Group S.p.A.
Report Date
May 07, 2026 For Q1 26
Estimate
$0.10
Actual
$0.11
Surprise
+5.45%
Crinetics Pharmaceuticals, Inc.
Report Date
May 07, 2026 For Q1 26
Estimate
-$1.26
Actual
-$1.23
Surprise
+2.51%
Nektar Therapeutics
Report Date
May 07, 2026 For Q1 26
Estimate
-$1.62
Actual
-$1.82
Surprise
-11.88%
Definium Therapeutics, Inc. Common Shares
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.50
Actual
-$0.71
Surprise
-41.43%
FAQ
What were KalVista Pharmaceuticals, Inc. Common Stock's earnings and revenue for the latest quarter Q4 2025?
For Q4 2025, KalVista Pharmaceuticals, Inc. Common Stock reported EPS of $0.91, beating estimates by 291.25%, and revenue of --, -- -- expectations.
How did the market react to KalVista Pharmaceuticals, Inc. Common Stock's Q4 2025 earnings?
The stock price moved up 4.13%, changed from $16.46 before the earnings release to $17.14 the day after.
When is KalVista Pharmaceuticals, Inc. Common Stock expected to report next?
The next earning report is scheduled for --.
What are the forecasts for KalVista Pharmaceuticals, Inc. Common Stock's next earnings report?
Based on --
analysts, KalVista Pharmaceuticals, Inc. Common Stock is expected to report EPS of -- and revenue of -- for Q-- --.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement